Dash Anil K, Panda Abinash, Prusty Nilamadhaba, Satpathy Manas R, Bisoyi Sasmita K, Barik Prasanjit A
Department of ENT, FMMCH, Balasore, Odisha, India.
Department of Pharmacology, JKMCH, Jajpur, Odisha, India.
J Family Med Prim Care. 2024 Oct;13(10):4648-4651. doi: 10.4103/jfmpc.jfmpc_617_24. Epub 2024 Oct 18.
Caroverine is an antagonist of non-NMDA and NMDA glutamate receptors. Cochlear synaptic tinnitus arises from a synaptic disturbance of NMDA or non-NMDA receptors on the afferent dendrites of spiral ganglion neurons. This forms a basis for the use of caroverine in the treatment of tinnitus. Hence, the present study was carried out to find the effect of oral caroverine in the treatment of tinnitus.
This quasi-experimental study was carried out on sixty consecutive patients of tinnitus. Thirty patients were given the usual standard of care consisting of Tab. Cinnarizine 25mg twice daily along with fixed dose combination Cap. B-complex and Ginkgo biloba once daily for ninety days and thirty patients were given Cap. Caroverine 40mg, twice daily for ninety days. Outcome assessment was done using the tinnitus case history questionnaire, tinnitus handicap inventory score, and VAS. The data were analyzed using GraphPad Prism Trial Version. A value ≤ 0.05 was taken as statistically significant.
There was a significant improvement in the tinnitus case history questionnaire score at 90 days in patients suffering from mild tinnitus when treated with caroverine. There was a larger decrease in the tinnitus handicap inventory score at 90 days of treatment in the caroverine-treated patients. The median VAS showed an improvement in the caroverine-treated group. The overall reduction in tinnitus in the caroverine-treated group was 53.3% with an odds ratio, 95% CI of 0.375 (0.12-1.08).
Oral caroverine was found to be better than the usual standard of care in reducing mild cochlear synaptic tinnitus. It also improved sensory-neural hearing loss during the treatment period.
卡维林是一种非NMDA和NMDA谷氨酸受体拮抗剂。耳蜗突触性耳鸣源于螺旋神经节神经元传入树突上NMDA或非NMDA受体的突触紊乱。这为使用卡维林治疗耳鸣奠定了基础。因此，本研究旨在探讨口服卡维林治疗耳鸣的效果。
本准实验研究对60例连续的耳鸣患者进行。30例患者接受常规标准治疗，包括每日两次服用25mg桂利嗪片，以及每日一次服用固定剂量复方制剂的复合维生素B和银杏叶胶囊，持续90天；另外30例患者每日两次服用40mg卡维林胶囊，持续90天。使用耳鸣病例史问卷、耳鸣致残量表评分和视觉模拟量表进行结果评估。数据采用GraphPad Prism试用版进行分析。P值≤0.05被认为具有统计学意义。
使用卡维林治疗的轻度耳鸣患者在90天时，耳鸣病例史问卷评分有显著改善。在治疗90天时，卡维林治疗组患者的耳鸣致残量表评分下降幅度更大。卡维林治疗组的视觉模拟量表中位数显示有所改善。卡维林治疗组耳鸣的总体减轻率为53.3%，优势比为0.375（95%置信区间为0.12 - 1.08）。
发现口服卡维林在减轻轻度耳蜗突触性耳鸣方面优于常规标准治疗。在治疗期间，它还改善了感音神经性听力损失。
